We are live on ! Find out more
NRSN icon

NeuroSense Therapeutics
NRSN

10 hedge funds and large institutions have $347K invested in NeuroSense Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.13% less ownership

Funds ownership: 2.13% → 0% (-2.1%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

41% less funds holding

Funds holding: 17 → 10 (-7)

64% less capital invested

Capital invested by funds: $964K → $347K (-$618K)

88% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 8

Holders
10
Holders Change
-7
Holders Change %
-41.18%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
+$66.5K
2
Two Sigma Investments
Two Sigma Investments
New York
+$30.9K
3
UBS Group
UBS Group
Switzerland
+$19.1K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$282K
2
YAG
Yorkville Advisors Global
New Jersey
-$113K
3
Jane Street
Jane Street
New York
-$54.2K
4
HF
HRT Financial
New York
-$41K
5
Marshall Wace
Marshall Wace
United Kingdom
-$22.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
1
Squarepoint
New York
$119K +$66.5K +45,450 +91%
Morgan Stanley
2
Morgan Stanley
New York
$83K -$19.8K -13,500 -17%
MIH
3
Meitav Investment House
Israel
$50K – – –
Two Sigma Investments
4
Two Sigma Investments
New York
$26.4K +$30.9K +21,086 New
Commonwealth Equity Services
5
Commonwealth Equity Services
Massachusetts
$26K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$19.8K – – –
UBS Group
7
UBS Group
Switzerland
$18.3K +$19.1K +13,048 +810%
SS
8
SBI Securities
Japan
$1.82K -$4.39K -3,000 -67%
Jones Financial Companies
9
Jones Financial Companies
Missouri
$1.24K -$14.5K -9,919 -91%
Carson Wealth (CWM LLC)
10
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
Citadel Advisors
11
Citadel Advisors
Florida
– -$282K -149,243 Closed
YAG
12
Yorkville Advisors Global
New Jersey
– -$113K -60,000 Closed
Jane Street
13
Jane Street
New York
– -$54.2K -28,689 Closed
HF
14
HRT Financial
New York
– -$41K -21,694 Closed
Marshall Wace
15
Marshall Wace
United Kingdom
– -$22.4K -11,828 Closed
BNP Paribas Financial Markets
16
BNP Paribas Financial Markets
France
– -$12.9K -6,800 Closed
HC
17
Hurley Capital
New York
– -$12.3K -6,530 Closed
TIM
18
Total Investment Management
Arizona
– -$945 -500 Closed

NRSN Hedge Fund Activity: Q3 2025 in Review

10 of the 7,622 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q3 2025, worth a combined $347K — down 64% from $964K a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of NRSN and 1 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Squarepoint, adding an estimated $66.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $282K sold.

  • 10 institutional investors held NeuroSense Therapeutics (NRSN) as of Q3 2025, down from 17 in Q2 2025.
  • Funds reported $347K of NeuroSense Therapeutics stock for Q3 2025, down 64% quarter-over-quarter.
  • 1 fund opened new NeuroSense Therapeutics positions in Q3 2025 and 8 closed out, a net change of -7 holders.
  • The largest NeuroSense Therapeutics buyer in Q3 2025 was Squarepoint, an estimated $66.5K added.
  • The largest NeuroSense Therapeutics seller in Q3 2025 was Citadel Advisors, an estimated $282K sold.

Based on aggregated 13F filings for Q3 2025.